# Donald J. Hayden, Jr.

> Donald J. Hayden, Jr. is a Series B investor at Bristol-Myers Squibb backing Health Care. See 1 investments, check sizes, portfolio and contact details…

- Type: Angel Investor
- Fund: [Bristol-Myers Squibb](https://shizune.co/investors/profile/bristol-myers-squibb)
- Total investments: 1
- Last investment: Apr 2014
- Lead investor: 0%
- Last updated: Aug 2026

Donald J. Hayden, Jr. is a Series B investor at Bristol-Myers Squibb focused on Health Care and Biotechnology. Don Hayden is a Senior Advisor to Prospect Venture Partners. Mr. Hayden brings to Prospect the experiences and perspective resulting from a highly-successful 25 year career with Bristol-Myers Squibb Company as well as the insights gained from key roles at a number of smaller, more entrepreneurial pharmaceutical and biotech companies over the past 5years. At Bristol-Myers Squibb, Mr. Hayden served as President of Global Pharmaceuticals; Executive Vice President and President, Americas, overseeing two major pharmaceutical units and two healthcare businesses; Executive Vice President of the Health Care Group; President of Oncology and Immunology; and Senior Vice President for Worldwide Franchise Management and Business Development.Since leaving Bristol-Myers Squibb in early 2006, Mr. Hayden has served as Chairman of Gloucester Pharmaceuticals, Vitae Pharmaceuticals, Insmed, and Azelon Pharmaceuticals, as Lead Director of Amicus Therapeutics, and as a Director of Otsuka Pharmaceuticals and Nora Therapeutics.Mr. Hayden received his undergraduate degree from Harvard University and has an M.B.A. from Indiana University.

## Contacts

5 contacts available for Donald J. Hayden, Jr.: work email, personal email, work phone, personal phone and socials. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-email/donald-j-hayden-jr?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 1 | 100% |
| Biotechnology | 1 | 100% |
| Medical Device | 1 | 100% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Nora Therapeutics | Nora Therapeutics is a specialty biopharmaceutical company focused on developing therapeutics to address clinical unmet needs in reproductive medicine.Nora’s lead compound, NT100, is a novel treatment being studied to improve pregnancy success rates and outcomes for women who have undergone multiple unsuccessful in vitro fertilization (IVF)procedures. NT100 is a novel biologic agent similar to a naturally occurring protein in the female reproductive tract. NT100’s mechanism of action may better enable embryo implantation and pregnancy maintenance by optimizing maternal-fetal immune tolerance. | $18M | Series B | Apr 17, 2014 |  |

1 of 1 investments shown.

## Co-investors
- [Burrill & Company](https://shizune.co/investors/profile/burrill-co) — VC Fund, 1 deal together
- [Novo Holdings](https://shizune.co/investors/profile/novo-a-s) — VC Fund, 1 deal together
- [Rho Ventures](https://shizune.co/investors/profile/rho-ventures) — VC Fund, 1 deal together
- [Vivo Capital](https://shizune.co/investors/profile/vivo-capital) — VC Fund, 1 deal together

## About Bristol-Myers Squibb

VC Fund · New York, United States

Bristol-Myers Squibb Company, through its subsidiaries, engages in the discovery, development, licensing, manufacturing, marketing, distribution, and sale of pharmaceuticals and nutritional products.

5 contacts available at Bristol-Myers Squibb.

| Name | Title | Profile |
| --- | --- | --- |
| John damonti | Foundation President | — |
| Chris Boerner | Executive Vice President, Chief Commercialization Officer | https://shizune.co/investors/profile/chris-boerner |
| Debra Boyko-DeBrito | Director Content Management Solutions | — |
| Donald J. Hayden, Jr. | President | — |
| Doug Bassett | SVP Informatics & Predictive Sciences | — |

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Donald J. Hayden, Jr. invest in?

Donald J. Hayden, Jr. invests primarily in Health Care, Biotechnology and Medical Device startups, most often at Series B stage. Most of the 1 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Donald J. Hayden, Jr.?

For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### When did Donald J. Hayden, Jr. last invest?

The most recent investment recorded for Donald J. Hayden, Jr. closed in Apr 2014. Shizune tracks 1 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co